Education
About Us
Working with TipRanks
Follow Us
Jamon Alexander Rahn Insider Profile
4 Followers
Jamon Alexander Rahn, Chief Executive Officer at Definium Therapeutics, holds 2.21M shares in Definium Therapeutics (Ticker: DFTX). Most recently, Jamon Alexander Rahn ― shares of Definium Therapeutics on ― for an estimated value of ―.
Jamon Alexander Rahn has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jamon Alexander Rahn's holdings
Insider Roles
Chief Executive Officer
Roles that Jamon Alexander Rahn holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jamon Alexander Rahn
Jamon Alexander Rahn's Trading History
List of latest transactions for each holding click on a transaction to see Jamon Alexander Rahn's performance on stock
You May Also Like
Jamon Alexander Rahn insider profile FAQ
What is the percentage of profitable transactions made by Jamon Alexander Rahn?
The percentage of profitable transactions made by Jamon Alexander Rahn is ―.
What is the average return per transaction made by Jamon Alexander Rahn?
The average return per transaction made by Jamon Alexander Rahn is ―.
What stocks does Jamon Alexander Rahn hold?
Jamon Alexander Rahn holds: DFTX stocks.
What was Jamon Alexander Rahn’s latest transaction?
Jamon Alexander Rahn latest transaction was an Uninformative Buy of ―.
What was Jamon Alexander Rahn's most profitable transaction?
Jamon Alexander Rahn’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jamon Alexander Rahn's role in Definium Therapeutics?
Jamon Alexander Rahn's role in Definium Therapeutics is Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.